Houston, TX, United States of America

Waldeman Priebe


Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2006-2015

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Waldeman Priebe: Innovator in Cancer Treatment

Introduction

Waldeman Priebe is a notable inventor based in Houston, TX, who has made significant contributions to the field of cancer treatment. He holds 2 patents that focus on innovative methods for combating brain tumors and developing new antibiotics.

Latest Patents

Priebe's latest patents include "Inhibitors of glycolysis useful in the treatment of brain tumors," which outlines methods for treating brain tumors by administering a therapeutically effective amount of specific compounds. Another significant patent is "Methods and compositions for the manufacture of C-3' and C-4' anthracycline antibiotics," which discloses novel substituted anthracyclines with modified alkyl-aromatic ring substitutions. This invention also details methods for preparing sugar substrates and anthracycline antibiotics, which have shown high cytotoxicity in vitro against various tumor cell lines.

Career Highlights

Throughout his career, Waldeman Priebe has worked with esteemed organizations such as the University of Texas System and Houston Pharmaceuticals, Inc. His work has been pivotal in advancing cancer treatment methodologies.

Collaborations

Priebe has collaborated with notable individuals in his field, including Charles A. Conrad and Timothy Madden. Their combined expertise has contributed to the development of innovative solutions in cancer research.

Conclusion

Waldeman Priebe's contributions to cancer treatment through his patents and collaborations highlight his role as an influential inventor in the medical field. His work continues to pave the way for advancements in therapeutic methods for brain tumors and antibiotic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…